Fractional exhaled nitric oxide (FeNO): the future of asthma care?
Kay Wang, Carol Stonham, Christine Rutherford, Ian Pavord
Abstract
Asthma affects around one in 30 people and contributes to nearly half a million deaths worldwide every year. 1 It is estimated that asthma will cost the UK NHS 1.3 billion in 2023, including costs relating to primary care contacts and prescription of treatments for asthma. 2 Treatments that aim to minimise risk of acute asthma exacerbations focus on reducing airway inflammation.However, despite significant advancements and increasing expenditure on asthma medications, incidences of asthma-related admissions to hospital and deaths have not improved over the last decade. 3This issue highlights the need for a more personalised 'treatable traits' approach 4 whereby treatments are targeted and optimised based on an individual's underlying disease